Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients

Journal of Clinical Psychiatry

Volumn 61, Issue 8, 2000, Pages 594-599

  Lu, M L ^a   Lane, H Y ^a   Chen, K P ^a   Jann, M W ^a   Su, M H ^a   Chang, W H ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOZAPINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; FLUVOXAMINE; FLUVOXAMINE MALEATE; KETOCONAZOLE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MALE; MENTAL DISEASE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033861422     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0809     Document Type: Article

References (41)

1. The economic impact of schizophrenia
2. The pharmacoeconomics of clozapine: A review
3. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
4. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
5. Pharmacokinetics and pharmaco-dynamics of clozapine
6. Maximizing clozapine therapy: Managing side effects
7. Fluvoxamine augmentation in clozapine-resistant schizophrenia: An open pilot study
8. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia
9. Co-administration of citalopram and clozapine: Effect on plasma clozapine levels
10. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
11. Clozapine drug-drug interactions: A review of the literature
12. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine
13. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes
14. Metabolism and bioactivation of clozapine by human liver in vitro
15. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
16. The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychiatric drugs and crosssectional study of side effects in neuroleptic-treated patients
17. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection
18. Determination of clozapine and desmethylclozapine in human plasma by high performance liquid chromatography with ultraviolet detection
19. Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics
20. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges
21. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients
22. Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage
23. Clozapine dosages and plasma drug concentrations
24. The use of other drugs to allow a lower dosage of cyclosporine to be used: Therapeutic and pharmacoeconomic considerations
25. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation
26. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
27. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine
28. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports
29. Extrapyramidal symptoms after addition of fluvoxamine to clozapine
30. Fluvoxamine increases the clozapine serum levels significantly
31. Elevated levels of clozapine in serum after addition of fluvoxamine
32. Clozapine and fluvoxamine, a curious complexity
33. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients
34. Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects
35. Dose-related plasma levels of clozapine: Influence of smoking behavior, sex, and age
36. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics
37. Relationship between patient variables and plasma clozapine concentrations: A dosing nomogram
38. Serotonin-dopamine interaction and its relevance to schizophrenia
39. Paroxetine and extrapyramidal reactions